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ABSTRACT
ALI (Acute lung injury) and its more fatal form ARDS (acute respiratory 
distress syndrome) together represent a broad spectrum of lung diseases, 
which are characterized by the abrupt onset of pulmonary inflammation 
with fluid filled alveoli resulting in hypoxia. With the advancement of 
several diagnostic tools, especially discovery of multiplex RT- PCR, 
increased the chance to investigate the involvement of different 
respiratory viruses in causing ARDS. There are several different viruses 
responsible for ARDS and among them few are capable of causing 
pandemic. Influenza viruses such as H5N1 and H1N1 causing pandemic 
in 2009. Also among different corona viruses, severe acute respiratory 
syndrome coronavirus (SARS- CoV), Middle East respiratory syndrome 
coronavirus (MERS- CoV) and most recently a novel betacoronavirus 
strain, severe acute respiratory syndrome coronavirus 2 (SARS- CoV- 2) 
have been identified. Till date, the therapy against virus induced ARDS 
has not been optimized. Naturally existing phytochemicals and plant 
biotechnology could offer prospective solutions for the treatment 
against virus induced ARDS by developing inhibitors, low- cost vaccines 
and antibodies, which could not only be useful for treatment but 
could also be used for diagnosis. In this present COVID- 19 pandemic, 
use of plant based therapeutic approach has already been adopted 
by several pharma companies to treat ARDS and there are several 
molecules currently under clinical trials with encouraging results. This 
review provides detailed outlook on ARDS pandemic causing viruses, 
pathophysiology of viruses and role of phytochemicals and plantibodies 
as anti- viral agent. Further, it summarizes list of phytochemicals and 
their mode of action in these pathogenic viruses.
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INTRODUCTION
Acute respiratory distress syndrome (ARDS) is 
a clinically defined pulmonary edema mainly 
arises due to a pulmonary inflammation, but does 
not involves cardiovascular system. According to 
European Society of Intensive Care Medicine in 2012 
ARDS is classified in three categories mild, moder-
ate and severe.1,2 High viral loads in lung can cause 
ARDS, chiefly by causing localized disease (pneumo-
nia) and/or systemic disease (sepsis, sepsis syndrome 
and septic).3 Viral induced lung damage can be 
broadly categorized into two classes: respiratory 
viruses, such as coronavirus, influenza virus induced 
community- acquired viral disease,4 and Herpes 
simplex virus (HSV) or cytomegalovirus (CMV) 
induced nosocomial viral infection.5,6 Community- 
acquired- pneumonia is most frequently caused 
by the influenza, rhinovirus and several strains of 
coronavirus.7,8 However in the last couple of decades 
five different viruses were foundto be responsible 
for major outbreak in pandemic scale causing acute 
respiratory failure and ARDS, which includes influ-
enza viruses9,10 and three different strains of beta- 
coronaviruses.11- 13 However the scariest pandemic 
(COVID- 19) spread recently in December, 2019 
by thesevere acute respiratory syndrome coronavi-
rus 2 (SARS- CoV- 2). SARS- CoV- 2, belongs to the 
family Coronaviridae in the order Nidovirales.10,14 
One common feature associated with SARS- CoV- 2 
& other related coronaviruses is initial low level of 
inflammatory response coupled with sudden burst of 
pro- inflammatory cytokines at the later time points. 
In fact, all the severe cases of COVID- 19 have been 
associated with excessive or uncontrolled levels of 
cytokines resulting in hyper inflammation, ARDS 
and mortality. This phenomenon commonly referred 
to as ‘Cytokine storms’ are a common complication 
not only in case of COVID- 19 but also in severe 
cases of SARS & MERS.15 According to the latest 
data by World Health Organization (WHO), up to 
the September, 2020, the number of confirmed cases 
in world reached 36,996,501 of which 1,069,476 were 
dead. Still the mortality graph isrising at a very fast-
erpace. This precarious situation is added up by the 
unavailabilityof vaccines or drug to protect human 
race against this epidemic. In the current situation 
when COVID- 19 pathogenesis was poorly under-
stood it is better to reuse the drugs/vaccines which 
are currently in hand.
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Purified natural products, traditional herbal 
medicines and genetically engineered plants consti-
tute a rich resource for novel antiviral biopharma-
ceuticals. For the last three decades, plant derived 
products become essential for the development 
of drugs, antibodies and vaccines against various 
pathogenic diseases including viral infections.16- 18 
Several natural compounds already shown high 
potential of anti- viral efficiency against different 
strains of influenza virus and coronavirus includ-
ing Severe acute respiratory corona virus (SARS- 
CoV)and Middle Eastern respiratory corona virus 
(MERS- CoV).17,19 However literature survey has 
also established the role of plant based substances 
as anti- inflammatory drugs, which proves useful 
to control delayed cytokine surge in different 
organs associated with influenza and corona virus 
infection20,21 and as SARS- CoV- 2 shares much of 
a sequence homology and pattern of transmission 
and viral entry into the host cell with other corona 
viruses and influenza viruses, use of these plant 
based substances could be found valuable in treat-
ment against SARS- CoV- 2 infection. This review 
first tried to explain the similar immune pathogen-
esis mechanisms of ALI and ARDS causing viruses 
(SARS- COV- 2 and other coronaviruses and influ-
enza viruses). Secondly, this article also explainsthe 
anti- viral potentials of different phytochemicals, 
discussing their anti- inflammatory properties with 
no or less side effects. We enlisted available plant 
based treatment against ARDS caused by influenza 
viruses along different corona viruses with a special 
reference to the recent research progress in SARS- 
CoV- 2 research and the knowledge from researches 
on ARDS.
EPIDEMIOLOGY OF VIRUSES CAUSING 
ARDS
ARDS basically consists of a wide range of diseases 
having severe infections both at pulmonary or 
extra- pulmonary regions. These infections may 
include one of the most common contagious 
form; Community- acquired pneumonia (CAP). 
ARDS may also be caused by viral infections of 
the lungs, ultimately resulting in tissue damages 
in the pulmonary and extra- pulmonary region.3 
CAP is one of the most common cause of develop-
ing ARDS and involvement of various respiratory 
viruses are recognized in patients with severe CAP 
and ARDS problems.22- 24 In 5- 10% cases of CAP, 
various strains of respiratory viruses are found to 
be responsible,4,25 among which influenza viruses 
and rhinoviruses are predominant.4,5 Other than 
these viruses, several seasonal respiratory viruses 
or pandemic viruses also caused viral pneumonia 
and ARDS,26 which are discussed below.
Respiratory viruses causing Seasonal 
outbreak
Seasonal viruses, which causes CAP most 
commonly include Respiratory Syncytial Virus 
(RSV), non- pandemic influenza, rhinoviruses, 
parainfluenza, adenovirus, coronaviruses, and 
human meta- pneumovirus(hMPV).These viruses 
cause up to 10% and in some case studies contrib-
uting up to 40% of the viral- induced seasonal 
outbreaks.4,25,27 Among these outbreaks, influenza 
and rhinoviruses can cause severe pneumonia, 
which could lead to ARDS.28,29 There are several 
subtypes of influenza & corona viruses, which are 
determined by presence of envelope glycoproteins 
having either hemagglutinins (HA) or neuramin-
idase (NA) enzyme activity30 or variations in the 
functional sites of receptor- binding domain (RBD) 
of the surface spike protein.31 High mutational 
ratesand recurrent genetic rearrangements in these 
viral proteins contribute to the increasing antigenic 
variabilityin these virus stains, resulting in new 
pandemic strains.
Respiratory viruses causing pandemic 
outbreaks
Over the past decade, five different viruses were 
accountable for acute respiratory failures and 
ARDS, which became pandemic are: severe acute 
respiratory syndrome corona virus (SARS- CoV) in 
2002, two influenza virus strains – avian influenza 
A H5N1 & influenza A H1N1 2009, the Middle East 
respiratory syndrome corona virus (MERS- CoV) in 
June, 2012 a novel beta- coronavirus strain severe 
acute respiratory syndrome coronavirus2 (SARS- 
CoV- 2) most recently in 2019 (Figure 1).26
Severe acute respiratory syndrome corona virus 
(SARS- CoV)
SARS- CoV was first recognized in in Guangdong, 
China, in November, 2002 and then spread fast 
globally to 29 different countries, resulting in 
more than 9.6% mortality32 with initial symptoms 
of shortness of breath and damage in the lung 
tissues, confirmed by chest X- rays in almost all the 
patients.32,33 20–30% of the SARS patients required 
ICU facility and a large number of them required 
mechanical ventilation (MV) to counter ARDS.33- 36 
SARS patients are treated with a combination ther-
apy of ribavirin, protease inhibitors, and INF that. 
However, none of these drug treatments was effec-
tive. Thus health personals mostly depend on good 
supportive care.37
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Influenza viruses- avian influenza A H5N1 and 
influenza A H1N1:
Severe pneumonia caused by avian influenza A 
virus- H5N1quickly progressed to ARDS with a 
high case- fatality rate (nearly 60%).38,39 Symptoms 
for H5N1 infection in humans are mostly nonspe-
cific, including fever, headache, vomiting, diarrhea, 
dyspnea, cough, etc. But in majority the pneumo-
nia rapidly causes ARDS mostly in aged people 
(>65year. However disease spread occurs due to 
avian to human transmission not due to human to 
human transmission.38,39 Majority of Patients are 
treated with high- dose oseltamivir (300 mg daily) 
for 10 days period and for oseltamivir- resistant 
H5N1 strain zanamivir used intravenously. In 2009, 
the influenza A H1N1 virus outbreak induces multi-
ple clinical syndromes like afebrile upper respira-
tory illness, fulminant viral pneumonia affecting 
mostly children and young adults.40 Symptoms for 
H1N1 infection in humans are mostly diffuse viral 
pneumonitis associated with severe hypoxemia 
and ARDS.9,40 Short incubation (24 hrs) period 
and rapid disease progression occurred in most 
of the cases. Viral infection detected in the entire 
respiratory tract. Like H5N1 oseltamivir and zana-
mivir used to treat patients with a good success 
rate.9,40- 42
Middle East respiratory syndrome coronavirus 
(MERS- CoV)
After a decade In June 2012, the first MERS case 
reported in Jeddah, Saudi Arabia. Nearly similar 
clinical symptoms are observed in MERS case 
which is characterized by progressive acute pneu-
monia. It affected all most all the age groups with a 
slight predominance for patients aged between 40 
to 50 years. MERS- CoV continues to infect humans 
sporadically in clusters of communities, and also via 
nosocomial infections in the Middle East regions. 
As of Feb 29, 2020, 2494 new cases of MERS- CoV 
infection have been registered worldwide with a 
mortality rate of 34·0%, majority from countries in 
Middle- East regions.43
Severe acute respiratory syndrome coronavirus 2 
(SARS- CoV- 2)
The current worldwide epidemic started from end 
of 2019 by novel Coronaviruses belong to the family 
Coronaviridae in the order Nidovirales44  Being a 
close relative of SARS- CoV and MERS- CoV this 
beta- coronavirus has shown similar symptom like 
fever, non- productive cough, dyspnea, myalgia, 
fatigue, normal or decreased leukocyte counts, and 
radiographic evidence of pneumonia in the upper 
respiratory tract which rapidly leads to ARDS.45 
SARS- CoV- 2 has mortality rate (~3%), with a 
much higher transmissibility (it spread to >200 
countries, within a period of three months).46 Still 
the numbers are increasing in a very high rate.
PATHOPHYSIOLOGY OF THE HUMAN 
RESPIRATORY VIRUSES CAUSING ARDS
Emergence of several zoonotic viruses appeared 
to be serious risk for the human population by the 
beginning of this century. Among them recurring 
appearance of different human respiratory viruses 
are much prevalent like SARS- CoV, avian influenza 
A H5N1, influenza A H1N1, MERS- CoV, SARS- 
CoV- 2. All these viruses cause respiratory disease 
with clinical manifestation varies from mild to 
even fatal cases of ARDS. The outcome of these 
viral infections are mostly common, which can be 
studied by comparing and associating their patho-
physiology. In general these viruses regulate a set 
of variable host factors, thus affecting host immune 
response, leading to the acute lung injury (ALI), 
severe pneumonia and ARDS. Understanding 
the pathophysiology of influenza and coronavi-
ruses will provide valuable information for the 
Figure 1  Schematic representation of the pathophysiology of acute respiratory 
distress syndrome (ARDS) and cytokine storm with possible effects. 
SARS- CoV- 2: Severe acute respiratory syndrome coronavirus 2; 
H5N: Avian influenza; ACEII: Angiotensin- converting enzyme 2; 
SA: Sialic acid receptors. Following entry of SARS- CoV- 2/H5N1 
into the host, the virus uses its spike protein to bind to ACE2/SA 
receptors, invading the respiratory airway epithelial cells, causing 
damage to the upper respiratory epithelium. Subsequently its 
releases pro- inflammatory cytokines and interleukins like IL- 6, 
IL- 18, TNF- α, IFN- γ and several other factors that can further 
trigger inflammation (Inflammasome activation) especially in 
the lower respiratory tract. Activation of macrophages also takes 
place to amplify the inflammatory cascade resulting in cytokine 
storm syndrome Excessive cytokine release resulting in damage 
and destruction of the lung tissue leading to widespread damage of 
blood capillaries in the lungs
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development of vaccine/therapeutic drugs against 
these viral infections.
Pathophysiology of Influenza viruses
Influenza A viruses infection involve a wide variety 
of disease spectrum in respiratory tract, ranging 
from mild upper respiratory symptoms to acute 
respiratory failure and ARDS.47 Infection with 
influenza viruses results in some common and 
nonspecific symptoms like fever, dyspnea, cough, 
diarrhea, etc. along with severe conditions like 
acute respiratory failure and ARDS.39 This severe 
hypoxemic respiratory failure and ARDS were 
also hallmarks of the 2009 influenza pandemic, 
which ultimately leads to the ICU admissions for 
most of the patients.40 Reports stated that there is 
a correlation between viral load and the severity of 
the respiratory infection with an enlarged risk of 
the requirement of mechanical ventilation facility.48 
Influenza viruses mainly targets alveolar epithelial 
cells, which are the preliminary defense layer to 
protect against respiratory infections.49 Histological 
studies revealed that influenza A (H1N1) virus 
infection is associated with diffuse alveolar damage 
with inflammation, leading to fibrosis and edema 
in the lung tissue along with uniform distribution 
of viral antigens throughout the lung parenchyma.50 
Early exposure of the virus to the alveolar macro-
phages results in the advancement of the disease, 
damaging the gas exchange to allow exposure of 
viruses to the endothelial cells.51 Disintegration 
of this fragile layer leads to the huge production 
of pro- inflammatory cytokine upon viral antigen 
exposure to the endothelial layer that further stim-
ulates the host derived innate and adaptive immune 
responses.52 The viral infection further targets innate 
immune pathways, amplifyingpro- inflammatory 
signals and contribute to the formation of inflam-
masome. This also stimulates secretion of IL- 1β and 
IL- 18 secretion that has been associated in numer-
ous studies as influenza- associated pathology.53 
Following cytokine and chemokine release, neutro-
phil and inflammatory monocytes are recruited to 
the alveolar tissue, leading to the tissue- damage by 
producing Matrix metalloproteinase(MMPs) and 
by secreting extracellular traps (NETs).54,55
This inflammatory response is initiated with the 
recognition of the pathogen- associated molecular 
pattern (PAMP) from the virus by the host pattern 
recognition receptors (PRRs) of innate immune 
cells,56 releasing huge amount of pro- inflammatory 
cytokines57 from the host cells, sometimes denoted 
as “cytokine storm”.58 Activation of PRRs further 
stimulates c- Jun N- terminal kinase (JNK), which 
induce translocation of NF- kB to the nucleus 
to produce pro- inflammatory cytokines.59 This 
inflammatory circuit further escalates cytokine 
storm.60 Severe cytokine storm is markedlyrelated 
with higher levels of pro- inflammatory cytokines 
such as interferons (IFNs),61,62 tumor necrosis 
factors (TNFs),63 interleukins (ILs),59 and chemok-
ines, identified in ARDS patients.38 Also, chemok-
ines sped up the process of tissue damage by specific 
chemotactic activities that recruited monocytes and 
T- lymphocytes to migrate into the site of inflam-
mation.64 These chemotactic activities are aided by 
several proteins like IL- 8, monocyte chemoattrac-
tant protein MCP- 1, interferon- induced protein 
(IP)- 10, macrophage inflammatory protein (MIP)- 
1, and monokines induced by IFN- c (MIG), which 
were found abnormally elevated in severe H5N1 
influenza infection, in which IL- 8 and MCP- 1 were 
mostly dominant.65 Both CD4 and CD8 T cells are 
also responsible for the lethal lung injury associated 
with influenza infection in humans. This injury can 
be triggered by the interaction between antigen- 
specific CD8 T cells and the influenza HA antigen.66 
ARDSassociated with influenza infection can also 
be characterized by the early secretion of CD4 T 
cell mediated Th1 and Th17 cytokines.67
Pathophysiology of Corona viruses
Gross pathology of the SARS- CoV, MERS- CoV, 
SARS- CoV- 2 and other human corona virus 
infection exhibits a variable degree of consolida-
tion, edema, congestion of the lungs, along with 
diffuse alveolar damage (DAD) at the respiratory 
tract. Although the severity of the infection leads 
to the ARDS, which depends on the viral loads 
and exposure. The corona virus infection also 
leads to the fibrosis in the alveolar epithelial cells, 
hemorrhage and also stimulates inflammatory 
cells like monocytes, macrophages, lymphocytes 
and neutrophils to infiltrate in alveolar wall and 
lamina.68- 71 Similar to the Influenza virus cases, the 
development of ARDS in the more severe form of 
viral infections with SARS- CoV, MERS- CoV or 
SARS- CoV- 2 in human cases may be related to 
several factors like induction of cytokines, chemok-
ine etc. The severe corona virus induced pulmonary 
damage may be endorsed due to an excessive host 
immune response mediated by the production of 
pro- inflammatory cytokines like type I IFNs, IL- 12, 
IL- 6 etc.45,72,73 In the blood of SARS- CoV, MERS- 
CoV or SARS- CoV- 2 infected patients with ARDS 
condition, the level of different chemokines such as 
IP- 10, MCP- 1, CXCL- 1, CXCL2, and IL- 8 etc. also 
get up- regulated.73- 75 Literature survey also stated 
that, the elevated levels of cytokine and chemok-
ine in corona virus infected patients are associated 
with the increasing accumulation of neutrophils 
and monocytes in the patients’ lung tissues and 
peripheral blood, suggesting that these cells may 
play a role in ARDS pathophysiology.76- 78 The high 
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level of cytokine and chemokine rapidly attract 
many inflammatory cells, such as neutrophils and 
monocytes, resulting in extreme infiltration of the 
cells into lung and thus causing severe damage to 
the lung tissue or triggering ARDS. Pulmonary 
recruitment of these cells along with lymphopenia 
(a rapid decrease of CD4+ and CD8+ T cells) is also 
a hallmark of SARS- CoV- 2 infection as more than 
80% of patients with SARS- CoV- 2 infection show-
ing this condition.78,79 Presence of high amount of 
neutrophils and other inflammatory cells causes 
ARDS by secreting excessive proteases and reactive 
oxygen species.80,81 This affects the efficiency of 
gas exchange through alveoli, causing difficulty in 
breathing, hypoxia and also increases the chance of 
secondary infection in the lungs.82,83 The elevated 
levels of cytokines, chemokine, and increasing infil-
tration of inflammation together can cause septic 
shock and multi- organ failure, along with myocar-
dial damage and circulatory failure in extreme 
cases.84- 86
DEVELOPMENT OF PROPHYLACTIC 
AND THERAPEUTIC TREATMENTS 
AGAINST ARDS
Presently, there is no specific treatment for virus 
induced ALI or it’s more severe form:ARDS.
Although, corticosteroids have been used for the 
treatment of ALI for several years. But it didn’t 
show promising results in clinical trials and have 
been found with several side effects in corticoste-
roids treated patients with ALI.87,88 Other clinically 
used anti- inflammatory drugs also been reported 
having several disadvantages, which includes 
adverse effects and a high cost. Thus the use of plant 
based vaccines and therapeutic drugs for the treat-
ment of ALI/ARDS could fill up this gap. Several 
phytochemicals have been traditionally used for the 
treatment against inflammation and have shown 
promising results with less or zero side effects.46,89
‘Antiviral agent’ against ARDS
Nearly 40% of currently available drugs came from 
phytochemical resources either directly utilizing 
phytochemicals or a synthesized product.90 The 
term ‘antiviral agent’ indicates all those compounds 
(other than vaccine and antibody) which can provide 
a protective or therapeutic effect to viral infected 
host.According to World Health Organization 
(WHO) majority of people from underdeveloped 
countries dependent on cheap phytochemical as 
their medicinal source. In this context, some of the 
medicinal plants and their respective compounds 
used for the treatment against virus induced ALI/
ARDS are summarized in Table 1.
Search against potential antiviral phytochemical 
can be carried either through random screening of 
phytochemicals or based on traditional knowledge, 
practices and Ethno- pharmacology. However it was 
found that the second approach is more successful 
than the previous one.91 From long agemedicinal 
plants were successfully used against various respi-
ratory and immunological disorders (like bronchial 
asthma, cold, cough etc.).92 Different plants derived 
compounds are already reported for their antiviral 
activity against ARDS causing virus. Lists of antivi-
ral compounds are summarized in Table 2.
Vaccines against ARDS
A vaccine is a therapeutic preparation usually 
administered for developing active immunity for an 
infectious disease. Now a day’s, molecular farming 
is utilized where plants are used as bioreactors to 
produce vaccines.93 Efficient mass scale synthe-
sis of genetically engineered proteins, decreasing 
contamination risk, easy and cheap purification 
method remains the major advantages for this 
plant based biopharmaceuticals production.94 Plant 
vaccine candidates against swine influenza,ra-
bies,andhepatitisB are already entered in clinical 
trial. To fight against ARDS causing virus several 
approaches has been adoptedto develop vaccine 
(Table 2). Although none of them are available till 
now in the market but many of have entered in the 
clinical trials (Table  3).18 In the current COVID- 
19 scenario the need of plant based vaccine esca-
lated several times. The knowledge of previous 
plant vaccines helps to reach that goal quickly and 
efficiently.
Plants are also genetically engineered to form 
human antibodies or part of antibodies and subse-
quently used as a vaccine for therapeutic cause 
and the term “Plantibodies” has been created to 
describe these products. It is considered as an effec-
tive technique as plants have already been proven 
to produce wide varieties of proteins that are free of 
mammalian toxins and pathogens.
The global pandemic caused due to COVID- 19 
virus has prompted the scientific community to 
divulge all their available resources to battle against 
the pathogen. In this respect several companies and 
research groups have started developing antibodies 
against COVID- 19 in search of a vaccine.. Medicago 
Inc. reported successful production of VLPs against 
S protein of SARS- CoV- 2 virus in huge capacity in a 
transient expression system (www.medicago.com/
en/pipeline/). Many other companies like iBio-
inc. (www.ibioinc.com/pipeline), Nomad (www.
nomadbioscience.com/), Ventria (ventria.com/), 
Greenovation Biopharmaceuticals (www.greenova-
tion.com/), protalix (ww.protalix.com) along with 
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Table 1  Phytochemicals derived from medicinal plants and their mode of action
Virus Medicinal plant Plant product Mode of action Reference
SARS- CoV Lycoris radiate Lycorine, isolated fromLycoris radiate NA 95
Glycyrrhiza glabra Glycyrrhizin NA 96
Houttuynia cordata Aquous extract of whole plant Inhibiting the viral 3CL 
protease and blocking 
the activity of viral RNA- 
dependent RNApolymerase2
97
Boenninghauseniasessilicarpa Leptodactylone NA 98
Hippeastrum hybrid Lectins (Agglutinins:mannoses pecific) present in 
diaminopropane extract
inhibiting viral attachment 











Tulipa hybrid Lectins (GlcNAc- specific) present in 
diaminopropane extract
Morus nigra Gal- specific present in diaminopropane extract
Nicotiana tabacum Lectins (Man/Glc- specific) present in 
diaminopropane extract
Urtica dioica Lectins(Gal/GalNAc- specific) present in 
diaminopropane extract
Morus nigra Lectins (GalNAc(>Gal)specific) present in 
diaminopropane extract
Cladastris lutea Lectins (GalNAcα(1.3)Gal>Gal NAc>) present in 
diaminopropane extract
Polygonatum multiflorum Lectins(Gal- specific) present in diaminopropane 
extract
Iris hybrid Lectins (Man/GalNAc- specific) present in 
diaminopropane extract
Artemisia annua 95% EtOH extract ofWhole plant NA 95
Pyrrosia lingua Chloroform extract ofleaf NA
Lindera aggregate 95% EtOH extract ofroot NA
Lycoris radiata lycorine NA
SARS- CoV 
BJ01





Toona sinensis Water extract of leaf Inhibits ofviral growth 101
Laurus nobilis Essential oils present in β- ocimene, 1,8- cineole, 
α- pinene, β- pinene
Inhibits of viral replication 102
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Table 1  Continues
Virus Medicinal plant Plant product Mode of action Reference
SARS- CoV 
PUMC01 F5
Cinnamomi sp. Procyanidin A2 Play roles in Early 
stage inhibition of 






Rheum officinale Emodin Inhibisbinding of S protein 
toACE2
105




Isatis indigotica Sinigrin, Indigo, β- sitosterol, Aloe- emodin and 
Hesperetin
Inhibis 3CLpro 106
Rheum palmatum Possiblyanthraquinones Inhibis 3CLpro 107
Salvia miltiorrhiza Tanshinone IIA,Tanshinone IIB, Methyl 
tanshinonate, Cryptotanshinone, Tanshinone I, 
Dihydrotanshinone Iand Rosmariquinone
NA 108
Torreya nucifera Amentoflavone,Bilobetin, Ginkgetin, 
Sciadopitysin
NA 109
Salvia miltiorrhiza Tanshinone IIA,Tanshinone IIB, Methyl 





Broussonetia papyrifera 3’- (3- methylbut- 2- enyl)- 3’,4,7- trihydroxyflavane Inhibis SARS- CoV Plpro.
Psoralea corylifolia Bavachinin, Neobavaisoflavone, Isobavachalcone, 
4’- O- methylbavachalcone, Psoralidin 
andCorylifol A
Inhibis SARS- CoV Plpro. 110
Paulownia tomentosa Tomentin (A- E) Inhibis SARS- CoV Plpro. 111
MARS- CoV Broussonetia papyrifera Kazinol F, Broussochalcone A Inhibis MARS- CoVPlpro. 112
Influenza 
virus
Sambucus nigra Extract of fruit A randomized, double- 
blinded A randomized, 
double- blindedan efficient, 
safe and cost- 
effective treatment for 
influenza
113
Allium oreoprasum Methanolic and methanolic- aqueous extracts influenza surface 
glycoprotein hemagglutinin 
(HA) is a potential target for 
antiviral drugs because of its 
key roles in the initial stages 
of infection: receptor binding 






Asparagus filicinus steroidal saponins,furostanol glycosides, 
furostanosides
NA 115
Chaenomeles sinensis high molecular weightpolyphenols NA 114
Myrica rubra ethanol extract NA
Verbascum Thapsus methanolic andmethanolic- aqueous extracts NA 115
Berginia ligulata Plant extract NA 116
Caesalpinea sappan Sappan chalcones NA 117
Gardenia sp. Plant extract NA 118
Glycyrrhiza glabra Glycyrrhizin NA 96
Neerium indicum Plant extract NA 116
Punica granatum Plant extract NA 119
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Table 1  Continues




Buch.- Ham. ex D.Don. 
(Asparagaceae)
Methanolic and methanolic- aqueous extracts Influenza surface 
glycoprotein hemagglutinin 
(HA) is a potential target for 
antiviral drugs because of its 
key rolesin the initial
stages of infection: receptor 




Verbascum thapsus L. 
(Scrophulariaceae)







Flavonoids: baicalein,baicalin, and wogonin NA 114





Ethanol extract NA 120
H1N1 Alpinia officinarium Diaryl heptanoids NA 118
Andrographis paniculata Andrographolide NA 121
Ephedra sinica Catechinc NA 122
Pandanus amaryllifoius Pandanin NA 123
Prunus mume Lectin- like molecule(s)isolated from the fruit- 
juice
NA 114
Curcuma longa Plant extract 124
Sambucus nigra Plant extract
H5N1 Andrographis paniculata Plant extract
H3N2 Prunus mume Lectin- like molecule(s) isolated from the fruit- 
juice
NA 114
Scutellaria baicalensis Flavonoids: baicalein,baicalin, and wogonin NA











Scutellaria indica Flavonoids: baicalein,baicalin, and wogonin NA
Selaginella sinensis Amentoflavone,IC50 of5.5 μg/ml NA 114
Barleria prionitis Iridoids NA
Glycyrrhiza glabra Glycyrrhizin NA 96
Wickstroemia indica Daphnoretin NA 126
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Table 1  Continues
Virus Medicinal plant Plant product Mode of action Reference
Newcastl e Avicennia marina Methanolic extract NA 127
Nigelia sativa Plant extract NA
Zizyphus spira- christi Plant extract NA
Adenovir us Artimisai princepsvar.
orientalis
hot water (HW) extract NA 114
Ardisia squamulosa hot water extract NA
Boussingaultia gracilis 
varpseudobaselloides
hot water (HW) extract NA
Serissa japonica hot water (HW) extract NA
Ocimum basilicum Apigenin, Linalool, andUrolic Acid NA
Table 2  Classified phytochemicals targeting ARDS causing viruses
Phytochemicals Bioactivity Targeting ARDS Virus Reference
Lycorine Ribonucleoprotein complex inhibit viral replication H5N1 128
HCoV- OC43, MERS- CoV 129
Mannose specific Lectins Lectins bind N- Glycosylation sites on Spike Protein inhibiting 
viral attachment
RSV, H1N1, H5N1 130
SARS- CoV 99
Procyanin A2 Interact with sialic acid binding site of Hemagglutinin. H5N1, H1N1 131
Target clathrin mediated endocytic pathways SARS- CoV 96
Emodin In IAVs, it induce anti- inflammatory pathway Nrf2. H5N1, H1N1, H3N2 132
In CoVs, it binds and inhibit Spike protein with ACE- II 
receptor.
SARS- CoVs 97
Sinigrin Anti- inflammatory role by inhibiting TNF- α H5N1, H1N1, H3N2 133
Targeted inhibition of 3C- Like proteases SARS- CoVs 98
Tanshinone Targeted inhibition of 3C- Like proteases SARS- CoVs 100
Kazinol F Targeted inhibition of 3C- like and papain- like (nsp3) proteases SARS- CoVs 112
Tomentin A Targeted inhibition papain- like (nsp3) proteases SARS- CoVs 111
Baicalein Inhibit neuraminidase activity of influenza virus HINI, 134
Targeted inhibition of 3C- Like proteases SARS- CoVs 135
Table 3  List of plantibodies designed against ARDS viruses
Target Virus Target protein and Vaccines type Major Advantages Reference
SARS- CoV- 1 S protein; multiepitope vaccines Expressed of SARS- CoV- 1 Spike protein (S1) N- terminal 
fragment in stably transformed tomato and low- nicotine 
tobacco plants. This helped to induce IgA and IgG responses in 
mice.Process allows inheritable antigen production and seed 
bank generation;
136
SARS- CoV- 1 S protein; multiepitope vaccines Expressed GFP tagged partial SARS- CoV- 1 S protein (amino 
acids 1- 658) was in transiently transformed tobacco leaves 
and stably transformed in both tobacco and lettuce. No 
immunizationassays were performed.Expressed SARS- CoV- 1 
nucleo protein transformed Nicotianabenthamiana. This helped 
to induce high levels of IgG1 and IgG2a in mice along with up 
regulation of IFN- γ and IL- 10 in splenocytes.This transient 
nuclear genome transformation approach helps in rapid 
production and quick implementation atthe industrial level.
137- 139
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different academic institutions are also working in 
the field of molecular farming (S R Mendoza, 2020).
CONCLUSION
Outbreak of covid- 19 has led to a worldwide emer-
gency situation to develop an antidote. In this 
scenario,development of plant vaccine, discovery 
of a phytochemical antiviral agent or repurposing 
of the traditional plant- based antiviral drugs can 
combat the virus in an urgent basis. Even in pres-
ence of advanced supportive treatment ARDS still 
is a threat to health professionals due to its high 
patient morbidity and mortality along with high 
cost treatment. Natural phytochemicals are always 
a vital source of antiviral chemical compounds and 
already shown much promise as potential antiviral 
compounds against ARDS caused by viruses. The 
information regarding extract, antiviral compounds, 
vaccine, derived from plant consolidate in this 
review may be useful for ARDS treatment caused 
by SARS- CoV- 2. The knowledge of compounds like 
Leptodactylone, Lectins, Glycyrrhizin, Lycorine, 
Luteolin and Tetra- O- galloyl- β- D- glucose, etc.could 
accelerate drug discovery or vaccines development 
to fight against SARS- CoV- 2 induced ARDS. Along 
with this development formation of monoclonal 
plantibody may provide another treatment process 
by substituting convalescent plasma transfusion 
method in a much less expensive and safer approach.
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Table 3  Continue
Target Virus Target protein and Vaccines type Major Advantages Reference
SARS- CoV- 1 multiepitope vaccines Expressed GFP tagged partial SARS- CoV- 1 S protein 
(amino acids 1- 658) was in transplastomic tobacco plants. 
This transplastomic technology provideshigher productivity, 






Haemagglutinin (HA);VLP vaccines Intramuscular (i.m.) immunization in mice twice through 
combination of i.m. priming and (intranasal) i.n. boosting. 
High levels of antibodies titers found. Less amount of virus 
particle detected in lung homogenate with comparison 








Haemagglutinin (HA); VLP vaccines In a Phase II clinical trial,due to single dose immunization 
(Alhydrogel as an adjuvant) homologous and heterologous 
antigen- specific CD4+ T cells were generated along with 





Haemagglutinin (HA); VLP vaccines The plant- made VLPs were isolated, subjected to endosomal 







Haemagglutinin (HA); VLP vaccines Better Tcell response found due to administration of plant- 
made vaccine to mice than inactivated H1N1 vaccine







Haemagglutinin (HA); VLP vaccines Upon exposure of plant- made VLPs to mice and human 
dendritic cells better in activation of CD4+ and CD8+ T cells 
recorded along with vitro higher IL- 6, IL- 10, and TNFα and 
CD83 expression.







Haemagglutinin (HA); VLP vaccines Upon exposure of plant- made VLPs to mouse dendritic cells 
interaction with activated antigen- presenting cells similar to the 
wild type virus.
146
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